Navigation Links
New Study Published in Lancet Respiratory Medicine Highlights QIAGEN's QuantiFERON-TB Potential to Predict Active Tuberculosis Risk in Infants
Date:2/16/2017

HILDEN, Germany and GERMANTOWN, Maryland, February 16, 2017 /PRNewswire/ --

Results Suggest Benefits of Quantitative Screening of Young Children in Countries With High TB Burden 

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that data published in The Lancet Respiratory Medicine journal shows screening with QuantiFERON-TB Gold (QFT) can detect latent tuberculosis (TB) infection in otherwise healthy young children and can predict which are likely to progress to the active stage of this life-threatening respiratory disease.

Continue Reading
QuantiFERON-TB blood test (PRNewsFoto/QIAGEN N.V.)
QuantiFERON-TB blood test (PRNewsFoto/QIAGEN N.V.)

(Photo: http://mma.prnewswire.com/media/468908/QuantiFERON_TB_Blood_Test.jpg )

Results from the study of more than 2,500 young children in South Africa suggest that screening with the modern QuantiFERON-TB blood test could save lives in countries with a high TB burden by identifying those children most at risk of developing active disease. The study noted young children are particularly vulnerable to TB, with up to 20% of those infected by the bacteria developing the active TB disease.

"This study marks a true milestone. For the first time, there is a test that has demonstrated the potential to quantify the risk for young children to develop active tuberculosis. Researchers found that those with a QuantiFERON-TB test result above a certain threshold were far more likely than others to get sick with the active disease. TB is a terrible killer of children in high-burden countries, so early diagnosis and treatment could save many lives," said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN.

Click here for full press release:

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={049783C5-174E-41FE-974D-1662A6DBD416}&lang=en

Contacts: QIAGEN Investor Relations John Gilardi +49-2103-29-11711 e-mail: ir@QIAGEN.com Public Relations Dr. Thomas Theuringer +49-2103-29-11826 e-mail: pr@QIAGEN.com


'/>"/>
SOURCE QIAGEN N.V.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Advocacy Study Highlights Top Locations for High-Growth Companies
2. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
3. New Study Shows Full Spectrum Endoscopy Procedure Reduces The Miss Rate of Adenomas During Colonoscopy
4. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
5. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
6. Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
7. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
8. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
9. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
10. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
11. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  A new tight-tolerance ... and other highly-engineered materials, is being launched by ... has been developed in recent years to service ... and surgical applications. More expensive materials such as ... microextrusion tubing due to their ability to consistently ...
(Date:5/3/2017)...  Getinge, a leading global provider of products ... cost efficiency within healthcare and life sciences, today ... demonstrating that intra-aortic balloon counterpulsation (IABC) appears effective ... The single-center, retrospective, observational study showed that use ... 50cc intra-aortic balloon (IAB) in contemporary practice ...
(Date:5/2/2017)... Iowa , May 2, 2017  CIVCO ... patient-centric radiotherapy solutions, announced today that Nat ... been with CIVCO since 2012 and has served ... management, senior vice president and general manager, and ... "I am extremely proud of what ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... , ... Orbita’s Nathan Treloar will discuss the role of voice-powered healthcare applications ... Connected Health and IoT: Technology Innovators and Disruption , the workshop is part of ... research and consulting firm specializing in emerging consumer technology products and services. , ...
(Date:5/23/2017)... ... , ... Patients in need of a pulpotomy in Mt. Horeb, ... with or without a referral. Dr. Cotey is a respected dental provider of general ... healthy alternative to a tooth extraction. , When a child has a severely infected ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... Today, Our ... Washington, MO with a public ribbon cutting ceremony. Since opening over a ... an alternative to the emergency room. The new Our Urgent Care walk-in clinic ...
(Date:5/22/2017)... ... ... Faithfully following pop culture, people today are forever in pursuit of physical ... programs. It carries on to skin nourished, pampered and nurtured to be soft and ... CDA has found that just like a perfectly cut and polished diamond, that ...
(Date:5/21/2017)... (PRWEB) , ... May 19, 2017 , ... ... pleased to announce the appointment of James (Jim) Vertino as Chief Information Officer ... a proven, transformational leader who drives innovation and business performance. He defines strategic ...
Breaking Medicine News(10 mins):